EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation

Elisa Hennings iD, Steffen Blum iD, Stefanie Aeschbacher iD, Michael Coslovsky iD, Sven Knecht iD, Ceylan Eken, Mirko Lischer iD, Rebecca E Paladini iD, Philipp Krisai iD, Tobias Reichlin iD, Nicolas Rodondi iD, Jürg H Beer iD und 16 weitere

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028255 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Elisa Hennings und 27 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Institute Basel University Hospital Basel, University of Basel Basel Switzerland. Hauptthemen laut MEDLINE: Atrial Fibrillation. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with atrial fibrillation (AF) face an increased risk of death and major adverse cardiovascular events (MACE). We aimed to assess the predictive value of the novel atrial‐specific biomarker BMP10 (bone morphogenetic protein 10) for death and MACE in patients with AF in comparison with NT‐proBNP (N‐terminal prohormone of B‐type natriuretic peptide). Methods and Results BMP10 and NT‐proBNP were measured in patients with AF enrolled in Swiss‐AF (Swiss Atrial Fibrillation Study), a prospective multicenter cohort study. A total of 2219 patients were included (median follow‐up 4.3 years [interquartile range 3.9, 5.1], mean age 73±9 years, 73% male). In multivariable Cox proportional hazard models, the adjusted hazard ratio (aHR) associated with 1 ng/mL increase of BMP10 was 1.60 (95% CI, 1.37–1.87) for all‐cause death, and 1.54 (95% CI, 1.35–1.76) for MACE. For all‐cause death, the concordance index was 0.783 (95% CI, 0.763–0.809) for BMP10, 0.784 (95% CI, 0.765–0.810) for NT‐proBNP, and 0.789 (95% CI, 0.771–0.815) for both biomarkers combined. For MACE, the concordance index was 0.732 (95% CI, 0.715–0.754) for BMP10, 0.747 (95% CI, 0.731–0.768) for NT‐proBNP, and 0.750 (95% CI, 0.734–0.771) for both biomarkers combined. When grouping patients according to NT‐proBNP categories (900 ng/L), higher aHRs were observed in patients with high BMP10 in the categories of low NT‐proBNP (all‐cause death aHR, 2.28 [95% CI, 1.15–4.52], MACE aHR, 1.88 [95% CI, 1.07–3.28]) and high NT‐proBNP (all‐cause death aHR, 1.61 [95% CI, 1.14–2.26], MACE aHR, 1.38 [95% CI, 1.07–1.80]).

Conclusions

BMP10 strongly predicted all‐cause death and MACE in patients with AF. BMP10 provided additional prognostic information in low‐ and high‐risk patients according to NT‐proBNP stratification. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02105844.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationHumansMaleMiddle AgedAgedAged, 80 and overFemaleCohort StudiesProspective StudiesBiomarkersPrognosisPeptide FragmentsNatriuretic Peptide, BrainBone Morphogenetic Proteins

Stichwörter der Autor:innen

BMP10MACEatrial fibrillationbone morphogenetic protein 10death

Substanzen

BiomarkersPeptide FragmentsNatriuretic Peptide, BrainBMP10 protein, humanBone Morphogenetic Proteins

Autor:innen und Institutionen

  • Cardiovascular Research Institute Basel University Hospital Basel, University of Basel Basel Switzerland.
  • Cardiology University Hospital Basel, University of Basel Basel Switzerland.
  • Department of Clinical Research University Hospital Basel, University of Basel Basel Switzerland.
  • Department of Cardiology Inselspital, Bern University Hospital, University of Bern Bern Switzerland.
  • Department of General Internal Medicine Inselspital, Bern University Hospital, University of Bern Bern Switzerland.
  • Institute of Primary Health Care (BIHAM) University of Bern Bern Switzerland.

ORCID-Profile: Elisa Hennings, Steffen Blum, Stefanie Aeschbacher, Michael Coslovsky, Sven Knecht, Mirko Lischer, Rebecca E Paladini, Philipp Krisai, Tobias Reichlin, Nicolas Rodondi, Jürg H Beer, Giulio Conte, Maria Luisa De Perna, Richard Kobza, Matthias Bossard, Peter Kastner, André Ziegler, Christian Müller, Otmar Pfister, Christine S Zuern, David Conen, Michael Kühne, Stefan Osswald

Zitieren

APA

Hennings, E., Blum, S., Aeschbacher, S., Coslovsky, M., Knecht, S., Eken, C., Lischer, M., Paladini, R. E., Krisai, P., Reichlin, T., Rodondi, N., Beer, J. H., Ammann, P., Conte, G., De Perna, M. L., Kobza, R., Blum, M. R., Bossard, M., Kastner, P., …, & Swiss‐AF Investigators (2023). Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028255

Vancouver

Hennings E, Blum S, Aeschbacher S, Coslovsky M, Knecht S, Eken C, et al. Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028255

BibTeX
@article{Hennings2023,
  author = {Hennings, Elisa and Blum, Steffen and Aeschbacher, Stefanie and Coslovsky, Michael and Knecht, Sven and Eken, Ceylan and Lischer, Mirko and Paladini, Rebecca E and Krisai, Philipp and Reichlin, Tobias and Rodondi, Nicolas and Beer, Jürg H and Ammann, Peter and Conte, Giulio and De Perna, Maria Luisa and Kobza, Richard and Blum, Manuel R and Bossard, Matthias and Kastner, Peter and Ziegler, André and Müller, Christian and Bonati, Leo H and Pfister, Otmar and Zuern, Christine S and Conen, David and Kühne, Michael and Osswald, Stefan and Swiss‐AF Investigators, Swiss‐AF Investigators},
  title = {Bone Morphogenetic Protein 10—A Novel Biomarker to Predict Adverse Outcomes in Patients With Atrial Fibrillation},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028255}
}
Kostenlos starten →